Cardioprotective effect and safety of dexrazoxane in all breast cancer stages in patients treated with anthracyclines with or without trastuzumab: a systematic review and meta-analysis.

Página do item simplificado
dc.creatorAriane Vieira Scarlatelli Macedo
dc.creatorAngelica Nogueira Rodrigues
dc.creatorRafael Brant Costa
dc.creatorAntonio Luiz Pinho Ribeiro
dc.date.accessioned2023-08-11T20:44:39Z
dc.date.accessioned2025-09-08T23:18:03Z
dc.date.available2023-08-11T20:44:39Z
dc.date.issued2019-09
dc.format.mimetypepdf
dc.identifier.issn0732-183X
dc.identifier.urihttps://hdl.handle.net/1843/57769
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofJournal of Clinical Oncology
dc.rightsAcesso Restrito
dc.subjectCancer de colo de útero
dc.subjectAntraciclinas
dc.subjectTrastuzumab
dc.subject.otherBreast cancer
dc.subject.otherAnthracyclines
dc.subject.otherTrastuzumab
dc.titleCardioprotective effect and safety of dexrazoxane in all breast cancer stages in patients treated with anthracyclines with or without trastuzumab: a systematic review and meta-analysis.
dc.typeArtigo de periódico
local.citation.epage79
local.citation.issue1
local.citation.spage68
local.citation.volume1
local.description.resumoOBJECTIVES: The authors performed a systematic review and meta-analysis of randomized and nonrandomized trials on the efficacy of dexrazoxane in patients with breast cancer who were treated with anthracyclines with or without trastuzumab.BACKGROUND: Breast cancer treatment with anthracyclines and trastuzumab is associated with an increased risk of cardiotoxicity. Among the various strategies to reduce the risk of cardiotoxicity, dexrazoxane is an option for primary prevention, but it is seldom used in clinical practice. METHODS: Online databases were searched from January 1990 up to March 1, 2019, for clinical trials on the use of dexrazoxane for the prevention of cardiotoxicity in patients with breast cancer receiving anthracyclines with or without trastuzumab. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model meta-analysis.RESULTS: Seven randomized trials and 2 retrospective trials with a total of 2,177 patients were included. Dexrazoxane reduced the risk of clinical heart failure (RR: 0.19; 95% CI: 0.09 to 0.40; p < 0.001) and cardiac events (RR: 0.36; 95% CI: 0.27 to 0.49; p < 0.001) irrespective of previous exposure to anthracyclines. The rate of a partial or complete oncological response, overall survival, and progression-free survival were not affected by dexrazoxane.CONCLUSIONS: Dexrazoxane reduced the risk of clinical heart failure and cardiac events in patients with breast cancer undergoing anthracycline chemotherapy with or without trastuzumab and did not significantly impact cancer outcomes.However, the quality of available evidence is low, and further randomized trials are warranted before the systematic implementation of this therapy in clinical practice.
local.publisher.countryBrasil
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.10072

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG